Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enarodustat in Chemotherapy-Induced Anemia
NCT06737081Phase 2Recruiting
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Sep 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enarodustat in anemia (2 arms), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. Primary endpoint: Incidence of Adverse events by CTCAE5.0. Started Sep 2024; status: recruiting.
02
Drugs
enarodustat
03
Conditions
anemia
Beyond the preview
Go deeper on NCT06737081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06737081.